Trial reportExperimental and clinical psychopharmacology2011
Galantamine improves sustained attention in chronic cocaine users.
Trial report in Experimental and clinical psychopharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 42 citations in OpenAlex.
- Randomized placebo-controlled trial of galantamine in individuals with cocaine use disorder.Journal of substance abuse treatment · 2019Trial
- Double-Blind Placebo-Controlled Trial of Galantamine for Methadone-Maintained Individuals With Cocaine Use Disorder: Secondary Analysis of Effects on Illicit Opioid Use.The American journal on addictions · 2019Trial
- Feasibility and effects of galantamine on cognition in humans with cannabis use disorder.Pharmacology, biochemistry, and behavior · 2019Trial
- Effects of galantamine on smoking behavior and cognitive performance in treatment-seeking smokers prior to a quit attempt.Human psychopharmacology · 2018Trial
- Neuropsychological Assessment Battery-Screening Module (S-NAB): performance in treatment-seeking cocaine users.The American journal of drug and alcohol abuse · 2014Trial
- Galantamine attenuates some of the subjective effects of intravenous nicotine and improves performance on a Go No-Go task in abstinent cigarette smokers: a preliminary report.Psychopharmacology · 2012Trial
- Cognitive effects of the acetylcholinesterase inhibitor, donepezil, in healthy, non-treatment seeking smokers: a pilot feasibility study.Drug and alcohol dependence · 2012Trial
- Galantamine and Computerized Cognitive Behavioral Therapy for Cocaine Dependence: A Randomized Clinical Trial.The Journal of clinical psychiatryTrial
- Structural brain changes associated with cocaine use and digital cognitive behavioral therapy in cocaine use disorder treatment.Drug and alcohol dependence reports · 2024Article
- Cocaine Use Disorder (CUD): Current Clinical Perspectives.Substance abuse and rehabilitation · 2022Review
- A mechanistic overview of approaches for the treatment of psychostimulant dependence.Frontiers in pharmacology · 2022Review
- Cognitive dysfunction in individuals with cocaine use disorder: Potential moderating factors and pharmacological treatments.Experimental and clinical psychopharmacology · 2019Review
- Self-reported cognitive scales in a US National Survey: reliability, validity, and preliminary evidence for associations with alcohol and drug use.Addiction (Abingdon, England) · 2017Article
- A threshold model for opposing actions of acetylcholine on reward behavior: Molecular mechanisms and implications for treatment of substance abuse disorders.Behavioural brain research · 2016Review
- Cognitive Function as a Transdiagnostic Treatment Target in Stimulant Use Disorders.Journal of dual diagnosis · 2016Review
- Neuroimaging and biomarkers in addiction treatment.Current psychiatry reports · 2014Review
- A critical review of the literature on attentional bias in cocaine use disorder and suggestions for future research.Experimental and clinical psychopharmacology · 2014Review
- Decision-making impairment predicts 3-month hair-indexed cocaine relapse.Psychopharmacology · 2014Article
- Future pharmacological treatments for substance use disorders.British journal of clinical pharmacology · 2014Review
- Cognitive function during nicotine withdrawal: Implications for nicotine dependence treatment.Neuropharmacology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Chronic cocaine users are known to have cognitive deficits that are predictive of poor treatment response. Whether these deficits improve with medications targeting specific cognitive functions has not been examined in previous studies. The goal of this study was to evaluate galantamine's efficacy on selected cognitive outcomes, including measures of sustained attention, response inhibition, and attentional bias in recently abstinent cocaine users. Galantamine, a reversible and competitive inhibitor of acetylcholinesterase, is used clinically in the treatment of Alzheimer's dementia. In a randomized, double-blind, parallel-group study, 34 participants were randomized to galantamine (8 mg/day) or placebo treatment for 10 days. Cognitive and self-report mood measures were obtained at baseline and on Days 5 and 10 after the initiation of treatment. Galantamine treatment, compared to placebo, improved the reaction time, F(2, 50) = 8.6, p < .01, detection sensitivity (A'), F(2, 50) = 4.9, p < .03, number of hits, F(2, 50) = 4.2, p < .04, and number of correct rejections, F(2, 50) = 5.6, p < .02, on the Rapid Visual Information Processing task. With the exception of speeding the reaction time on the Stroop, galantamine did not affect performance on other tasks, (p > .05). These results demonstrate that medications can enhance cognitive function (e.g., sustained attention) in abstinent cocaine users. The potential efficacy of galantamine as a treatment for cocaine abuse needs to be further evaluated in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.